Its portfolio includes roxadustat, approved for treating anemia in chronic kidney disease patients across multiple regions, and FG-3246, an innovative antibody-drug conjugate targeting CD46 in ...

Good day and welcome to the FibroGen third-quarter 2024 earnings conference call. (Operator Instructions) Please note this event is being recorded. I would now like to hand the call over to David ...

Advances in cardiac imaging techniques and risk categorization have led to improvements in diagnosis, initial treatment and ...